ReviewWorld journal of hepatology2016
Chronic hepatitis C: This and the new era of treatment.
Abstract readReview
In one paragraph
Review in World journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance.Nutrients · 2017Trial
- Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.BMC psychiatry · 2016Trial
- Are there any non-invasive methods to predict liver fibrosis in children infected by hepatitis C virus rather than liver biopsy?Clinical and experimental hepatology · 2026Article
- Factors associated with chronic kidney disease among patients with hepatitis c infection attending Kigeme district hospital, Rwanda.Scientific reports · 2026Article
- Article
- A data-driven approach to hepatitis C forecasting using machine learning and epidemiological models.PloS one · 2026Article
- Development of a Multiple-Epitope-Based Vaccine for Hepatitis C Virus Genotypes 1a and 1b: an in-silico reverse vaccinology approach.In silico pharmacology · 2024Article
- Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital.Tropical medicine and infectious disease · 2023Article
- A novel candidate hepatitis C virus genotype 4 subtype identified by next generation sequencing full-genome characterization in a patient from Saudi Arabia.Frontiers in microbiology · 2023Article
- Progression of Antiviral Agents Targeting Viral Polymerases.Molecules (Basel, Switzerland) · 2022Review
- Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.World journal of hepatology · 2022Review
- Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C.Diagnostics (Basel, Switzerland) · 2022Article
- Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis.Respiratory medicine · 2021Article
- Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C.Journal of clinical medicine · 2021Article
- Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2).Health psychology research · 2020Article
- Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons.Open forum infectious diseases · 2020Article
- Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Observational
- Hepatitis C Virus Infection Increases Fatigue in Health Care Workers.Diseases (Basel, Switzerland) · 2020Article
- Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.International journal of molecular sciences · 2020Article
- Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments.AJP reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Gaetano BertinoGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Annalisa ArdiriGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Maria ProitiGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Giuseppe RiganoGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Evelise FrazzettoGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Shirin DemmaGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Maria Irene RuggeriGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Laura ScuderiGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Giulia MalaguarneraGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Nicoletta BertinoGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Venerando RapisardaGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Isidoro Di CarloGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Adriana ToroGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Federico SalomoneGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Mariano MalaguarneraGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Emanuele BertinoGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Michele MalaguarneraGaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last years it has started a real revolution in the treatment of chronic hepatitis C. This occurred for the availability of direct-acting antiviral agents that allow to reach sustained virologic response in approximately 90% of cases. In the near future further progress will be achieved with the use of pan-genotypic drugs with high efficacy but without side effects.
Indexed as
BoceprevirDaclatasvirDasabuvirDirect-acting antiviral agentsFaldaprevirHepatitis CLedipasvirNucleoside inhibitorsOmbitasvirRitonavirSimeprevirSofosbuvirTelaprevir
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.